IADR Abstract Archives
THE EFFECTS OF ANTI-ANGIOGENTIC DRUGS ON ENDOTELIAL PROGENITOR CELLS AND THEIR IMPACT ON MRONJ
Objectives: To investigate the effects of anti-angiogenic drugs on EPC's, their impact on MRONJ and to search for a marker that may predict the development of MRONJ.
Methods: EPCs were isolated and cultivated. Cells morphology was examined and analyzed by flow cytometry. Based on their expressed surface markers, cells were classified into early EPCs and late EPCs. The cells functionality was farther investigated and compared to cells treated with Bevacizumab using tube formation assay, in vitro migration and sprouting assays. The expression of angiogenic genes was also investigated in these cells using real-time PCR.
Results: Late EPCs had statistically higher proportion of cells expressing KDR, CD14 and CD31. Late EPCs could sprout and migrate, however they could not if seeded onto medium with Bevacizumab. A decrease in the expression of angiogenic genes was noted in cells treated with Bevacizumab.
Conclusions: These preliminary results suggest that Bevacizumab effect the functionality of EPC's which responsible for vascularization. Farther in vivo and in vitro assays can facilitate the search for a specific marker in the development of MRONJ and may predict the proper timing for surgical interventions in patients receiving Bevacizumab.
Methods: EPCs were isolated and cultivated. Cells morphology was examined and analyzed by flow cytometry. Based on their expressed surface markers, cells were classified into early EPCs and late EPCs. The cells functionality was farther investigated and compared to cells treated with Bevacizumab using tube formation assay, in vitro migration and sprouting assays. The expression of angiogenic genes was also investigated in these cells using real-time PCR.
Results: Late EPCs had statistically higher proportion of cells expressing KDR, CD14 and CD31. Late EPCs could sprout and migrate, however they could not if seeded onto medium with Bevacizumab. A decrease in the expression of angiogenic genes was noted in cells treated with Bevacizumab.
Conclusions: These preliminary results suggest that Bevacizumab effect the functionality of EPC's which responsible for vascularization. Farther in vivo and in vitro assays can facilitate the search for a specific marker in the development of MRONJ and may predict the proper timing for surgical interventions in patients receiving Bevacizumab.